{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:27Z","timestamp":1790806827080,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00417-021-05137-9","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T15:02:26Z","timestamp":1616338946000},"page":"2849-2855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity"],"prefix":"10.1007","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5421-8580","authenticated-orcid":false,"given":"Tomoya","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomichi","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Oshika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"5137_CR1","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. N Engl J Med 367:2515\u20132526","journal-title":"N Engl J Med"},{"key":"5137_CR2","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1097\/01.iae.0000244293.94251.20","volume":"26","author":"BR Hurley","year":"2006","unstructured":"Hurley BR, McNamara JA, Fineman MS et al (2006) Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina 26:S16\u2013S17","journal-title":"Retina"},{"key":"5137_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333","journal-title":"JAMA Ophthalmol"},{"key":"5137_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","volume":"44","author":"E McLoone","year":"2007","unstructured":"McLoone E, O\u2019Keefe M, McLoone S, Lanigan B (2007) Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 44:170\u2013173","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"5137_CR5","first-page":"228","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6:228\u2013236","journal-title":"Int J Ophthalmol"},{"key":"5137_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5137_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"5137_CR8","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E et al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101:365\u2013370","journal-title":"Br J Ophthalmol"},{"key":"5137_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0002-9440(10)63448-7","volume":"163","author":"S Sarlos","year":"2003","unstructured":"Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL (2003) Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 163:879\u2013887","journal-title":"Am J Pathol"},{"key":"5137_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4161\/org.6.2.11687","volume":"6","author":"JM Rosenstein","year":"2010","unstructured":"Rosenstein JM, Krum JM, Ruhrberg C (2010) VEGF in the nervous system. Organogenesis 6:107\u2013114","journal-title":"Organogenesis"},{"key":"5137_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212\u20132219","journal-title":"Ophthalmology"},{"key":"5137_CR12","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137:e20153218","journal-title":"Pediatrics"},{"key":"5137_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA (2018) Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 22:61\u201365.e1","journal-title":"J AAPOS"},{"key":"5137_CR14","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 11:e0148019","journal-title":"PLoS One"},{"key":"5137_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"key":"5137_CR16","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group (2004) Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233\u2013250","journal-title":"Trans Am Ophthalmol Soc"},{"key":"5137_CR17","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft DI, He M, Jonas JB et al (2019) IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 60:M20\u2013M30","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5137_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/ped.12969","volume":"58","author":"K Kawabe","year":"2016","unstructured":"Kawabe K, Kondo S, Matsumoto M et al (2016) Developmental quotient to estimate intelligence in autism spectrum disorder. Pediatr Int 58:963\u2013966","journal-title":"Pediatr Int"},{"key":"5137_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1440-1819.2009.01931.x","volume":"63","author":"T Koyama","year":"2009","unstructured":"Koyama T, Osada H, Tsujii H, Kurita H (2009) Utility of the Kyoto Scale of Psychological Development in cognitive assessment of children with pervasive developmental disorders. Psychiatry Clin Neurosci 63:241\u2013243","journal-title":"Psychiatry Clin Neurosci"},{"key":"5137_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/archdischild-2019-316793","volume":"105","author":"J Shibasaki","year":"2020","unstructured":"Shibasaki J, Mukai T, Tsuda K et al (2020) Outcomes related to 10-min Apgar scores of zero in Japan. Arch Dis Child Fetal Neonatal Ed 105:64\u201368","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"5137_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122:1008\u20131015","journal-title":"Ophthalmology"},{"key":"5137_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","volume":"192","author":"YS Lee","year":"2018","unstructured":"Lee YS, See LC, Chang SH et al (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20\u201330","journal-title":"Am J Ophthalmol"},{"key":"5137_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F et al (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218\u2013226","journal-title":"Ophthalmology"},{"key":"5137_CR24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","volume":"4","author":"AE Hamad","year":"2020","unstructured":"Hamad AE, Moinuddin O, Blair MP et al (2020) Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retina 4:602\u2013612","journal-title":"Ophthalmol Retina"},{"key":"5137_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","volume":"37","author":"JM Yoon","year":"2017","unstructured":"Yoon JM, Shin DH, Kim SJ et al (2017) Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina 37:88\u201396","journal-title":"Retina"},{"key":"5137_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280\u2013283","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"5137_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.eye.6700295","volume":"17","author":"L Gnanaraj","year":"2003","unstructured":"Gnanaraj L, Brennan R, Cottrell DG (2003) Retinopathy of prematurity in practice II: long-term results following treatment for threshold disease. Eye (Lond) 17:189\u2013193","journal-title":"Eye (Lond)"},{"key":"5137_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150\u2013158.e1","journal-title":"Am J Ophthalmol"},{"key":"5137_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","volume":"126","author":"HP Gerber","year":"1999","unstructured":"Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149\u20131159","journal-title":"Development"},{"key":"5137_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jpeds.2005.01.047","volume":"146","author":"MC Walsh","year":"2005","unstructured":"Walsh MC, Morris BH, Wrage LA et al (2005) Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 146:798\u2013804","journal-title":"J Pediatr"},{"key":"5137_CR31","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00431-020-03650-3","volume":"179","author":"ES Novitskaya","year":"2020","unstructured":"Novitskaya ES, Dahlmann-Noor AH, Adams GGW, Allen LE (2020) Retinopathy of prematurity treatment in the UK: trends in neonatal anaesthetic support and location of treatment from a national surveillance study. Eur J Pediatr. 179:1603\u20131607","journal-title":"Eur J Pediatr."},{"key":"5137_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 246:1061\u20131063","journal-title":"Graefes Arch Clin Exp Ophthalmol."}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05137-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T02:08:44Z","timestamp":1629684524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05137-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5137"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05137-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}